share_log

HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $16 Price Target

Benzinga ·  Sep 8, 2023 07:09

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment